melatonin (Slenyto®)

Status: Under consideration by AWMSG Scrutiny Panel
Treatment of insomnia in children and adolescents aged 2-18 years with neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient. Treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
Medicine details
Medicine name	melatonin (Slenyto®)
Formulation	prolonged release tablets
Reference number	7100
Indication	As above
Company	Flynn Pharma Ltd
BNF chapter	Central nervous system
Assessment type	Under consideration
Status	Under consideration by AWMSG Scrutiny Panel
Scrutiny Panel meeting date	03/11/2025